NCT06123884 - BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | Biotech Hunter

Enrollment

526

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

January 31, 2027

Conditions

Cervical Cancer

Interventions

DRUG

Recombinant humanized anti-PD-1 monoclonal antibody injection

Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).

DRUG

Cisplatin

the usage and dosage should be determined by the investigator

DRUG

Bevacizumab Injection

Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)

DRUG

carboplatin

the usage and dosage should be determined by the investigator

DRUG

Paclitaxel for Injection

the usage and dosage should be determined by the investigator

Trial Locations (1)

RECRUITING

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan